Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

DBS for Depression

NCT: NCT03437928 · RECRUITING

NCT IDNCT03437928
StatusRECRUITING
Start Date2019-08-20
Completion2026-08-19
SponsorBaylor College of Medicine (OTHER)
First posted
Last updated

Brief Summary

The goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 specific aims: 1. Demonstrate device capability to selectively and predictably engage distinct brain networks 2. Delineate depression-relevant networks and demonstrate behavioral changes with network-targeted stimulation 3. Demonstrate that chronic DBS using steered, individualized targeting is feasible and safe for reducing depressive symptoms

Frequently Asked Questions

What is DBS for Depression?

DBS for Depression is a clinical trial registered under NCT03437928. Current status: RECRUITING.

What is the status of NCT03437928?

The current status of NCT03437928 (DBS for Depression) is: RECRUITING.

When did DBS for Depression start?

DBS for Depression started on 2019-08-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.